Malignancy Clinical Trials

191 recruitingLast updated: June 17, 2026

There are 191 actively recruiting malignancy clinical trials across 34 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Boston, Massachusetts, United States, Hangzhou, Zhejiang, China, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Malignancy Trials at a Glance

191 actively recruiting trials for malignancy are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 2 with 60 trials, with the heaviest enrollment activity in Boston, Hangzhou, and Houston. Lead sponsors running malignancy studies include Cancer Research UK, St. Jude Children's Research Hospital, and Massachusetts General Hospital.

Browse malignancy trials by phase

Treatments under study

About Malignancy Clinical Trials

Looking for clinical trials for Malignancy? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignancy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignancy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 191 trials

Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1Phase 2

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

CholangiocarcinomaBile Duct NeoplasmBiliary Tract Malignancy
National Cancer Institute (NCI)31 enrolled1 locationNCT04645160
Recruiting

Response to Influenza Vaccination in Pediatric Oncology Patients

Hematologic MalignancyPediatric CancerTransplant-Related Cancer
St. Jude Children's Research Hospital150 enrolled1 locationNCT05384288
Recruiting
Phase 2

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical CancerMetastatic CancerAnal Cancer+18 more
Christian Hinrichs20 enrolled3 locationsNCT05686226
Recruiting
Phase 1Phase 2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical CancerAnal CancerPenile Cancer+14 more
Christian Hinrichs15 enrolled2 locationsNCT05639972
Recruiting
Phase 3

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Solid TumorHematologic MalignancyAdvanced Malignancies
Novartis Pharmaceuticals50 enrolled15 locationsNCT06401356
Recruiting

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

Solid TumorHematologic MalignancyB-ALL
St. Jude Children's Research Hospital100 enrolled5 locationsNCT06579469
Recruiting
Phase 1

Phase I Study of HRS-3005 in B-cell Malignancies

B-cell Malignancy
Jiangsu HengRui Medicine Co., Ltd.190 enrolled1 locationNCT07556822
Recruiting
Not Applicable

Sedation Methods in Percutaneous Transhepatic Biliary Drainage: Procedure Quality and Recovery

MalignancyFragilityCholangitis+1 more
Ankara City Hospital Bilkent98 enrolled1 locationNCT07640243
Recruiting
Phase 1Phase 2

Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.

Solid TumorHematologic Malignancy
Chinese PLA General Hospital24 enrolled1 locationNCT07570563
Recruiting
Phase 1

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

Metastatic Solid TumorsAdvanced Solid CancersAdvanced Malignancy
Adcytherix SAS290 enrolled9 locationsNCT07238075
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 1

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Hematologic Malignancy
St. Jude Children's Research Hospital30 enrolled1 locationNCT07052370
Recruiting
Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Malignancy
Alliance for Clinical Trials in Oncology240 enrolled626 locationsNCT04242095
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Not Applicable

Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

Solid TumorHematologic MalignancySickle Cell Disease+3 more
Washington University School of Medicine60 enrolled1 locationNCT06689800
Recruiting

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

LymphomaLeukemiaHematologic Malignancy
National Cancer Institute (NCI)88 enrolled1 locationNCT06856226
Recruiting

Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products

Relapsed Hematologic MalignancyRefractory Hematologic Malignancy
St. Jude Children's Research Hospital1,000 enrolled1 locationNCT05713214
Recruiting
Phase 1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477